References
- Jaffe S. 21st Century Cures Act progresses through US Congress. Lancet 2015;385:2137–8.
- Printz C. House passes 21st Century Cures Act: legislation would boost NIH funding, speed drug development. Cancer 2015;121:4101–12.
- Servick K. U.S. senators advance biomedical innovation bills, but key NIH funding issue unresolved. Science; 2016. doi: 10.1126/science.aaf9891. [serial on the Internet]; [cited 2016 June 23]. Available from: http://www.sciencemag.org/news/2016/04/us-senators-advance-biomedical-innovation-bills-key-nih-funding-issue-unresolved.
- Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D productivity. Nat Rev Drug Discov 2012;11:191–200.
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 2016;47:20–33.
- Kesselheim AS, Wang B, Avorn J. Defining « Innovativeness » in drug development: a systematic review. Clin Pharmacol Ther 2013;94:336–48.
- Lanthier M, Miller KL, Nardinelli C, Woodcock J. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987–2011. Health Aff (Millwood) 2013;32:1433–9.
- Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8:959–68.
- Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov 2010;9:867–82.
- Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40–51.
- Daniel GW, Caze A, Romine MH, et al. Improving pharmaceutical innovation by building a more comprehensive database on drug development and use. Health Aff 2015;34:319–27.
- Stevens AJ, Jensen JJ, Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;343:535–41.